Brief: TRACON Pharmaceuticals Announces Results Of Independent Data Monitoring Committee Review Of 12 Week Safety Data From Envasarc Phase 2 Pivotal Trial - Trial To Proceed As Planned
06/10/2022 13:21
Oct 6 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS ANNOUNCES RESULTS OF INDEPENDENT
DATA
MONITORING COMMITTEE REVIEW OF 12 WEEK SAFETY DATA FROM ENVASARC
PHASE 2 PIVOTAL TRIAL - TRIAL TO PROCEED AS PLANNED
Source text for Eikon: ID:nGNX63S8dv
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants